ZNF585A Knockout cell line (A549)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZNF585A (zinc finger protein 585A) encodes a zinc finger-containing protein predicted to bind zinc ions and participate in regulation of RNA polymerase II-dependent transcription. Its predicted nuclear localization and zinc-binding activity are consistent with a potential role in transcriptional regulation through interactions with DNA or other nuclear proteins. However, the specific target genes, molecular partners, and physiological functions of ZNF585A remain incompletely characterized.

A549 is a human lung cancer cell line established in 1972 from an explanted lung tumor of a 58-year-old male patient. The cells exhibit characteristics of alveolar type II pulmonary epithelial cells, including the ability to synthesize lecithin through the cytidine diphosphocholine pathway. A549 cells have been described as originating from lung adenocarcinoma and are widely used as a model for studying lung cancer biology, pulmonary epithelial function, drug responses, and respiratory-related research.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.